Recent HPV Findings by Centers for Disease Control and Prevention Validate Advaxis, Inc.'s Treatable Population
The recent study found that a quarter of US women between the ages of 14 and 59 years are infected with the HPV virus. To date, there has not been data available on the prevalence of HPV across such a broad age range. The highest incidence was found in females from 20 to 24 years, 44.8 percent.
Commenting on the recent data, John Rothman, VP of Clinical Development at Advaxis stated, "The recent finding that 26% of US women between the ages of 14 to 50 are HPV positive and that 44% of women between 20-24 are HPV positive clearly defines the risk for women of the viral infection that is presumed to cause cervical cancer."
It is estimated that HPV is the most common sexually transmitted infection in the United States. High-risk types of HPV can cause cervical, anal and other genital cancers. Cervical cancer affects thousands of women each year. Currently, Merck's Gardasil and GlaxoSmithKline's Cervarix are being discussed as vaccine therapies for cervical cancer, but are only effective in targeted women who have never been exposed to HPV.
Lovaxin C is Advaxis' response to the unmet need for a therapeutic cancer vaccine to treat women who have been exposed to HPV and have cervical cancer or other forms of HPV related disease.
Rothman continued, "These women who have HPV will not be helped by any prophylactic treatment that requires them to be free of the virus at the time of vaccination, and the numbers indicate that the risk is growing. This is precisely the population that Advaxis' therapeutic agent, Lovaxin C, is intended to treat. Currently in clinical trials, Lovaxin C is intended to stimulate the body to recognize HPV as a foreign invader and to promote an immune response capable of curing HPV-induced disease. The first trial of this therapeutic agent is ongoing and early results have shown that it is safe."
Dr. Rothman concluded, "In the future, Lovaxin C would offer a non-surgical alternative to HPV-induced disease including cervical dysplasia and possibly cervical cancer, other HPV-related cancers, and other forms of disease that will be useful in addressing the high levels of HPV infection currently seen in women in the United States."
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis' is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Thomas A. Moore, 732-545-1590
Investor Relations Group
Investor: Michael Crawford, 212-825-3210
Media: Janet Vasquez, 212-825-3210
Posted: March 2007